Sandrine Boyault
YOU?
Author Swipe
View article: Management and survival of patients with cancer of unknown primary discussed by a French national multidisciplinary tumour board: a retrospective analysis
Management and survival of patients with cancer of unknown primary discussed by a French national multidisciplinary tumour board: a retrospective analysis Open
View article: Impact of Exercise on Clonal Hematopoiesis
Impact of Exercise on Clonal Hematopoiesis Open
View article: Broad versus limited gene panels to guide treatment in patients with advanced solid tumors: a randomized controlled trial
Broad versus limited gene panels to guide treatment in patients with advanced solid tumors: a randomized controlled trial Open
Large genomic programs have contributed to improving drug development in cancer. To assess the potential benefit of using larger gene panels to guide molecular-based treatments, we conducted a multicenter randomized trial in patients with …
View article: Interaction between APOE Ɛ4 status, chemotherapy and endocrine therapy on cognitive functioning among breast cancer survivors: the CANTO-Cog longitudinal study
Interaction between APOE Ɛ4 status, chemotherapy and endocrine therapy on cognitive functioning among breast cancer survivors: the CANTO-Cog longitudinal study Open
This study suggests APOE4 genotyping is ineffective for detecting cognitive impairment in BC. New genotypes should be identified to predict cognitive decline in BC.
View article: Supplementary Data and methods 4 from Metabolomic Prediction of Breast Cancer Treatment–Induced Neurologic and Metabolic Toxicities
Supplementary Data and methods 4 from Metabolomic Prediction of Breast Cancer Treatment–Induced Neurologic and Metabolic Toxicities Open
Supplementary Data and methods
View article: Supplementary Data 2 from Metabolomic Prediction of Breast Cancer Treatment–Induced Neurologic and Metabolic Toxicities
Supplementary Data 2 from Metabolomic Prediction of Breast Cancer Treatment–Induced Neurologic and Metabolic Toxicities Open
metabolic
View article: Supplementary Data 3 from Metabolomic Prediction of Breast Cancer Treatment–Induced Neurologic and Metabolic Toxicities
Supplementary Data 3 from Metabolomic Prediction of Breast Cancer Treatment–Induced Neurologic and Metabolic Toxicities Open
Neurotoxicity
View article: Supplementary Data 1 from Metabolomic Prediction of Breast Cancer Treatment–Induced Neurologic and Metabolic Toxicities
Supplementary Data 1 from Metabolomic Prediction of Breast Cancer Treatment–Induced Neurologic and Metabolic Toxicities Open
Supplementary Data 1
View article: Data from Metabolomic Prediction of Breast Cancer Treatment–Induced Neurologic and Metabolic Toxicities
Data from Metabolomic Prediction of Breast Cancer Treatment–Induced Neurologic and Metabolic Toxicities Open
Purpose:Long-term treatment-related toxicities, such as neurologic and metabolic toxicities, are major issues in breast cancer. We investigated the interest of metabolomic profiling to predict toxicities.Experimental Design:Untargeted high…
View article: A bio-behavioral model of systemic inflammation at breast cancer diagnosis and fatigue of clinical importance 2 years later
A bio-behavioral model of systemic inflammation at breast cancer diagnosis and fatigue of clinical importance 2 years later Open
View article: Added value of whole‐exome and <scp>RNA</scp> sequencing in advanced and refractory cancer patients with no molecular‐based treatment recommendation based on a 90‐gene panel
Added value of whole‐exome and <span>RNA</span> sequencing in advanced and refractory cancer patients with no molecular‐based treatment recommendation based on a 90‐gene panel Open
Introduction The objective was to determine the added value of comprehensive molecular profile by whole‐exome and RNA sequencing (WES/RNA‐Seq) in advanced and refractory cancer patients who had no molecular‐based treatment recommendation (…
View article: 145P Identification of biomarkers of survival across multiple cancer types using eXplainable artificial intelligence
145P Identification of biomarkers of survival across multiple cancer types using eXplainable artificial intelligence Open
View article: Sorafenib in Molecularly Selected Cancer Patients: Final Analysis of the MOST-Plus Sorafenib Cohort
Sorafenib in Molecularly Selected Cancer Patients: Final Analysis of the MOST-Plus Sorafenib Cohort Open
Background: MOST-plus is a multicenter, randomized, open-label, adaptive Phase II trial evaluating the clinical benefit of targeted treatments matched to molecular alteration in advanced/metastatic solid tumors. Sorafenib was tested on pat…
View article: Sorafenib in Molecularly Selected Cancer Patients: Final Analysis of the MOST-Plus Sorafenib Cohort
Sorafenib in Molecularly Selected Cancer Patients: Final Analysis of the MOST-Plus Sorafenib Cohort Open
Background: MOST-plus is a multicenter, randomized, open-label, adaptive Phase II trial evaluating the clinical benefit of targeted treatments matched to molecular alteration in advanced/metastatic solid tumors. Sorafenib was tested on pat…
View article: Figure S14 from Dissecting the Origin of Heterogeneity in Uterine and Ovarian Carcinosarcomas
Figure S14 from Dissecting the Origin of Heterogeneity in Uterine and Ovarian Carcinosarcomas Open
Complete clonal evolution of P05 tumor.
View article: FIGURE 1 from Dissecting the Origin of Heterogeneity in Uterine and Ovarian Carcinosarcomas
FIGURE 1 from Dissecting the Origin of Heterogeneity in Uterine and Ovarian Carcinosarcomas Open
Genomic landscape of CS. A, Tissue origin and histological subtypes for each tumor (from P01 to P15). B, Main component and detailed percentage content for both samples (a and b) derived from the same tumor. C, CNA ana…
View article: FIGURE 3 from Dissecting the Origin of Heterogeneity in Uterine and Ovarian Carcinosarcomas
FIGURE 3 from Dissecting the Origin of Heterogeneity in Uterine and Ovarian Carcinosarcomas Open
Differential expression and methylation analysis (C vs. S). A, Heatmap and pathway overrepresentation analysis of differentially expressed genes between C and S (or undifferentiated) components of the 10 samples derived from the fiv…
View article: FIGURE 4 from Dissecting the Origin of Heterogeneity in Uterine and Ovarian Carcinosarcomas
FIGURE 4 from Dissecting the Origin of Heterogeneity in Uterine and Ovarian Carcinosarcomas Open
Evolutionary histories of CS. Clonal lineage histories of P02 MSI phenotype tumor (A), P12 BRCAness-phenotype tumor (B), and P15 ovarian bilateral tumor (C). Left, Clonal lineage inference for the whole tumor: subclona…
View article: Figure S2 from Dissecting the Origin of Heterogeneity in Uterine and Ovarian Carcinosarcomas
Figure S2 from Dissecting the Origin of Heterogeneity in Uterine and Ovarian Carcinosarcomas Open
Heterogeneity of genomic rearrangements in carcinosarcoma.
View article: Supplementary Table 2 from Dissecting the Origin of Heterogeneity in Uterine and Ovarian Carcinosarcomas
Supplementary Table 2 from Dissecting the Origin of Heterogeneity in Uterine and Ovarian Carcinosarcomas Open
List of differentially expressed genes (paired analysis of 5 selected tumors).
View article: Figure S3 from Dissecting the Origin of Heterogeneity in Uterine and Ovarian Carcinosarcomas
Figure S3 from Dissecting the Origin of Heterogeneity in Uterine and Ovarian Carcinosarcomas Open
Clustering of CS mutational signatures with COSMIC signatures.
View article: Figure S3 from Dissecting the Origin of Heterogeneity in Uterine and Ovarian Carcinosarcomas
Figure S3 from Dissecting the Origin of Heterogeneity in Uterine and Ovarian Carcinosarcomas Open
Clustering of CS mutational signatures with COSMIC signatures.
View article: Figure S1 from Dissecting the Origin of Heterogeneity in Uterine and Ovarian Carcinosarcomas
Figure S1 from Dissecting the Origin of Heterogeneity in Uterine and Ovarian Carcinosarcomas Open
Collection and selection of tumor samples.
View article: Supplementary Table 1 from Dissecting the Origin of Heterogeneity in Uterine and Ovarian Carcinosarcomas
Supplementary Table 1 from Dissecting the Origin of Heterogeneity in Uterine and Ovarian Carcinosarcomas Open
Curated list of chromatin remodeling genes.
View article: Supplementary Table 3 from Dissecting the Origin of Heterogeneity in Uterine and Ovarian Carcinosarcomas
Supplementary Table 3 from Dissecting the Origin of Heterogeneity in Uterine and Ovarian Carcinosarcomas Open
List of differentially methylated gene promoters (paired analysis of 5 selected tumors).
View article: Figure S10 from Dissecting the Origin of Heterogeneity in Uterine and Ovarian Carcinosarcomas
Figure S10 from Dissecting the Origin of Heterogeneity in Uterine and Ovarian Carcinosarcomas Open
Analysis of common genomic events between paired tumor samples.
View article: FIGURE 4 from Dissecting the Origin of Heterogeneity in Uterine and Ovarian Carcinosarcomas
FIGURE 4 from Dissecting the Origin of Heterogeneity in Uterine and Ovarian Carcinosarcomas Open
Evolutionary histories of CS. Clonal lineage histories of P02 MSI phenotype tumor (A), P12 BRCAness-phenotype tumor (B), and P15 ovarian bilateral tumor (C). Left, Clonal lineage inference for the whole tumor: subclona…
View article: Figure S15 from Dissecting the Origin of Heterogeneity in Uterine and Ovarian Carcinosarcomas
Figure S15 from Dissecting the Origin of Heterogeneity in Uterine and Ovarian Carcinosarcomas Open
Complete clonal evolution of P12 tumor.
View article: Figure S8 from Dissecting the Origin of Heterogeneity in Uterine and Ovarian Carcinosarcomas
Figure S8 from Dissecting the Origin of Heterogeneity in Uterine and Ovarian Carcinosarcomas Open
Alteration of genes of RAS pathway in uterine and ovarian CS.
View article: FIGURE 2 from Dissecting the Origin of Heterogeneity in Uterine and Ovarian Carcinosarcomas
FIGURE 2 from Dissecting the Origin of Heterogeneity in Uterine and Ovarian Carcinosarcomas Open
Key gene alterations in uterine and ovarian CS. Oncoprint of alterations identified in the 50 most altered genes from TCGA cancer pathways and custom lists of CRG. The type of genomic alteration (deletion, amplification, fusion, broken by …